Virtual Symposium (CME Concluded): Challenges and Advances in the Diagnosis and Management of Heart Failure with Preserved Ejection Fraction

Prognosis and treatment of heart failure patients with preserved ejection fraction (HFpEF) is complicated by diagnostic challenges and complicated pathophysiologies. Compared to HF patients with reduced ejection fraction (HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning. The lack of specific therapies for HFpEF have contributed to the increased prevalence and prognosis of the disease, and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in managing HFpEF. Advancements in disease pathophysiology, diagnostic tools, current and emerging treatment options may give clinicians additional tools to improve the outcomes of the disease; including morbidity, mortality, and quality of life.

To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to diagnose and manage HFpEF, including patients with comorbidities. This symposium will also provide an overview on current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients.

Case Study

Chairperson: Mariell Jessup, MD

Diagnosis of HFpEF

Presenter: Ileana L. Piña, MD, MPH, FAHA, FACC

Treating HFpEF: The Current State of Pharmacotherapies

Presenter: Javed Butler, MD, MPH, MBA

Decreasing hospital readmission rates for HFpEF patients

Presenter: Alanna A. Morris, MD, MSc

Audience Q&A

Panel: All Faculty